June 26, 2026

This CEO Thinks Like a Chess Player: Building a $400M Biotech from Scratch

This CEO Thinks Like a Chess Player: Building a $400M Biotech from Scratch
YouTube podcast player iconSpotify podcast player iconApple Podcasts podcast player icon
YouTube podcast player iconSpotify podcast player iconApple Podcasts podcast player icon

Some of the best conversations are with the people you think you already know. In this episode of No Spotlight Needed, host Sheetal Mehta Prasad sits down with Dipal Doshi, CEO of Entrada Therapeutics, for an honest look at what it takes to build a biotech company with conviction.

Dipal was Entrada's first full-time employee. As a non-scientist, he helped take the company from an unproven hypothesis through its IPO and into active clinical development in one of the most competitive areas in biotech: Duchenne muscular dystrophy. What comes through is how intentional he is. He thinks like a chess player, always looking three or four moves ahead, and he blocks off every Friday just to keep asking the right questions.

Sheetal and Dipal get into Entrada's founding story, the winding career path that led him there, what it really takes to raise capital for an early stage company, leading through a clinical hold, the patient first culture his team has built, and how he stays grounded at home. His view on the industry says a lot: biotech is not a high failure business, it is a high hope one.

This conversation was recorded before Entrada's recent clinical data release. The leadership lessons are still very relevant, and the company's mission has not changed.


Let’s connect:

LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/

Our Website: https://www.nospotlightneeded.com/

Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe


Timestamps:

0:00 Cold open

2:09 Welcome to the show

2:13 A pivot that was not forced

2:48 Why he blocks off every Friday

4:39 Stewards of capital and careers

5:13 A liberal arts kid with a five year plan

6:25 What sales really teaches you

7:14 Consulting, then Eli Lilly and a North Star

8:21 Wharton, banking, and the capital markets

9:52 Raising 400 million dollars

12:20 The bet: proving you can get inside the cell

14:02 The Amicus years and John Crowley

17:50 Biotech is not high failure, it is high hope

19:12 How Entrada found him

22:49 The lunch that started a partnership

25:08 Going public during Covid

26:53 Living through a clinical hold

31:03 Building a culture people can feel

34:23 Patients on the wall

35:55 Cutting through the noise in DMD

38:14 The obligation to obsolete your own technology

39:29 Staying present at home

40:52 The loneliest job

43:28 Losing his father, and his mother's strength

45:19 Keep your North Star